My Member
Message Center
trending topics
market reports
-
Visit MEDICAL JAPAN 2023 TOKYO and take full advantage of the business opportunities!
2023-09-01
-
US to distribute 400 million free N95 masks at CVS, Walgreens in COVID fight
2022-01-21
-
Ethiopia receives additional 2.2 mln doses of Chinese-donated COVID-19 vaccines
2022-01-21
-
Hong Kong researchers say they develop novel material able to kill COVID-19 virus
2022-01-14
-
10 million more Chinese doses on way for Kenya
2022-01-14
-
Sino-African ties on track for a brighter future
2022-01-07
-
Efforts urged to boost COVID-19 vaccine production capacity in poor countries
2022-01-07
-
UAE approves Sinopharm's new protein-based COVID-19 vaccine
2022-01-07
-
UAE approves Sinopharm's new protein-based COVID-19 vaccine
2022-01-07
-
Zimbabwe buoyed by Chinese jabs
2021-12-31
China-developed COVID-19 vaccine to enter late-stage trial in Uzbekistan
2020-11-16
A staff member displays samples of the COVID-19 inactivated vaccine at Sinovac Biotech Ltd, in Beijing on March 16, 2020. [Photo/Xinhua]
TASHKENT -- The Uzbek government has recently told media that the country will carry out a phase-3 trial of a China-developed vaccine for COVID-19, which makes the vaccine China's fifth candidate to enter late-stage human tests overseas.
The ministry has announced that 5,000 Uzbek volunteers aged between 18 and 59 will attend the third phase of the pilot process, which will continue for a year.
Developed by China's Anhui Zhifei Longcom Biopharmaceutical, the trial vaccine has been transported to Uzbekistan along with several Chinese specialists who will work on the monitoring of participants and training of Uzbek doctors.
Uzbekistan has so far confirmed 69,830 COVID-19 cases and 594 deaths, with 67,092 patients recovered.
(China Daily)
